AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC) announced its participation in the upcoming Piper Sandler 38th Annual Healthcare Conference. Management is scheduled for a fireside chat on Tuesday, December 1, 2026, at 11:30 a.m. Eastern Standard Time. A live audio webcast will be available on the company's investor relations website.
A live audio webcast will be available for AtriCure’s Dec. 1 conference chat.
AtriCure, Inc. (Nasdaq: ATRC) announced its participation in the Piper Sandler 38th Annual Healthcare Conference. Management will hold a fireside chat on December 1, 2026, at 11:30 a.m. EST, with a live audio webcast accessible through the company's investor relations website. The company specializes in surgical treatments for atrial fibrillation and related conditions.
Form SCHEDULE 13G/A AtriCure, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Wellington Management Group LLP and its related entities have filed an amended Schedule 13G for AtriCure, Inc., indicating their beneficial ownership of 4,116,204 shares of common stock, representing 8.1% of the class. The filing details shared voting and dispositive power among the Wellington entities and certifies that the securities were acquired in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
A 4.12 million-share AtriCure (ATRC) stake is reported by investment advisers holding shares for clients.
Wellington entities have reported an 8.09% ownership stake in AtriCure, Inc. (ATRC), totaling 4,116,204 common shares. These shares are beneficially owned by clients of investment advisers within Wellington’s structure, granting clients rights to dividends or sale proceeds. The filing also details shared voting and dispositive power among several Wellington entities over these shares.
AtriCure (ATRC) Raised Guidance After A Profit Return, Is The Stock Cheap?
AtriCure (ATRC) recently reported strong third-quarter results, including higher revenue and a return to profit, leading to increased full-year 2026 guidance. Despite a short-term dip in share price, the company has shown significant momentum over the past 90 days and year-to-date. The stock's valuation presents mixed signals, with analysts seeing it as slightly undervalued, while its Price/Sales ratio suggests it trades at a premium compared to industry peers.
Stifel reiterates Buy rating on AtriCure stock after conference
Stifel maintained its Buy rating and $70.00 price target on AtriCure Inc. (NASDAQ:ATRC) after a management meeting at the Stifel Healthcare Conference. The firm noted positive indicators such as low-teens revenue growth sustainability and potential 2027 revenue growth acceleration, driven by innovation and strong performance in pain management. This outlook is supported by recent third-quarter results that exceeded market expectations, prompting BTIG to also raise its price target for AtriCure.
AtriCure Inc (A5I.MU) cash flow
This article provides detailed cash flow information for AtriCure Inc (A5I.MU), including annual and quarterly data for various cash flow activities. It presents cash flow from operating, investing, and financing activities, as well as supplemental cash flow metrics like free cash flow to firm and capital expenditure. The financial statements have been upgraded with a new layout for more detail.
Did Profitable Quarter Just Shift AtriCure (ATRC) Stock Investment Narrative?
AtriCure (ATRC) reported a profitable third quarter in 2026, with revenue of US$154.45 million and net income of US$4.06 million, marking a significant shift from previous losses. The company also provided full-year 2026 guidance, indicating sustained profitability. This development suggests that AtriCure's cost structure and product mix are now effectively supporting earnings alongside growing sales, potentially altering the investment narrative for the medical equipment company.
ATRC: BoxX, quality metrics and new products underpin growth catalysts from 2027 onward
AtriCure, Inc.'s (ATRC) FY26 guidance is based on cautious assumptions, despite strong U.S. performance. The company expects BoxX and the STS metric to drive growth from 2027 onwards, with increased investment in R&D and product development, while the hybrid segment faces pressure. This information is derived from the Stifel 2026 Healthcare Conference audio transcript on November 11, 2026.
AtriCure Board Member Sold $143K In Company Stock
AtriCure board member B. Kristine Johnson sold 2,452 shares of company stock for a total of $143,392 on November 10, according to an SEC filing. This insider transaction occurred while AtriCure shares were trading up by 0.81% at $56.72. The article also provides a detailed financial overview of AtriCure, highlighting its revenue growth, gross margin, EPS, debt management, and various valuation metrics.
AtriCure Inc. R (A5I.DU) stock price, news, quote and history
This page provides an overview of AtriCure Inc. R (A5I.DU) stock, including its current price, a summary of its performance, and links to news, charts, and financial data. The stock is listed on the Dusseldorf exchange and shows a price of 50.00 EUR with a 1.63% increase. The article also provides key financial statistics like market capitalization and profitability measures.
AtriCure Inc (A5I.HA) company profile and facts
This article provides a company profile for AtriCure Inc (A5I.HA), listing its current stock price and recent performance. It notes that key executive information, company description, and corporate governance scores are not available. The article also highlights an upcoming earnings date for AtriCure Inc on November 3, 2026.
AtriCure Inc (A5I.MU) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding AtriCure Inc. (A5I.MU), a medical device company. It highlights various updates including its stock performance, recent Q3 2026 earnings, raised guidance, and upcoming investor conference participations. The stock is currently trading at 55.00 EUR, showing a -5.17% decrease at close on November 6th, 2026.
AtriCure Inc (A5I.HA) stock price, news, quote and history
This page provides an overview of AtriCure Inc (A5I.HA) stock, including its current price, recent news, and historical data. It highlights the stock's performance against the S&P 500 and features recent articles discussing the company's Q3 earnings and 2026 guidance.
AtriCure Inc (A5I.HA) interactive stock chart
This Yahoo Finance page provides an interactive stock chart for AtriCure Inc (A5I.HA), showing its current price and performance. It also lists recent news articles related to AtriCure, including Q3 2026 earnings reports, analyst estimations, and upcoming investor conferences. The stock was trading at 51.00 EUR, down 2.86% at the close.
AtriCure Inc (A5I.MU) latest press releases and corporate news
This article provides the latest press releases and corporate news for AtriCure Inc (A5I.MU), including its recent financial results and participation in upcoming investor conferences. It also displays the company's stock performance compared to the S&P 500 benchmark.
Form 4 AtriCure Inc: Salvatore Privitera (Chief Technical Officer) For: 4 November
This article reports on a Form 4 filing for AtriCure Inc, detailing an insider transaction by Salvatore Privitera, the Chief Technical Officer, on November 4th. Form 4 filings are regulatory documents that disclose changes in the ownership of securities by a company's directors, officers, or principal stockholders. The article is brief and primarily serves as an alert for this financial disclosure.
AtriCure (ATRC) Shares Just Moved, So What Is Going On?
AtriCure (ATRC) recently announced strong third-quarter 2026 earnings, featuring higher revenue, a return to profit, and increased full-year guidance, leading to an 8.48% single-day stock gain. The market views AtriCure as 4% undervalued, with a fair value of $68, yet some analysts consider the stock expensive on sales with a P/S ratio of 5.7x. Investors are now weighing the company's new profitability against its current valuation risks.
JP Morgan maintains AtriCure at Neutral, raises price target to $62 from $36
JP Morgan has maintained its "Neutral" rating for AtriCure (ATRC) while significantly increasing its price target to $62 from $36, representing a 72.2% hike. This new price target suggests a 2.6% upside from the stock's closing price of $60.41 on November 3. Other analysts also recently reiterated "Buy" or "Overweight" ratings for AtriCure with price targets ranging from $68 to $70.
AtriCure stock hits 52-week high at $63.00
AtriCure Inc.'s stock reached a 52-week high of $63.00, trading at $63.69 with a market capitalization of $3.08 billion. The stock has seen an 84% increase over the past year and a 110% surge in the last six months, driven by strong investor confidence and impressive Q3 2026 financial results, which surpassed analyst expectations for earnings per share and revenue. BTIG subsequently raised its price target for AtriCure to $70.
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
AtriCure (NASDAQ: ATRC) reported strong third-quarter results, exceeding analyst expectations with earnings of 17 cents per share against an estimated loss of 5 cents, and sales of $154.450 million. Following these upbeat results, the company raised its FY2026 adjusted EPS guidance to 40 cents-46 cents per share and its sales guidance to $606.000 million-$610.000 million. BTIG and Needham analysts maintained their Buy ratings on AtriCure, both raising their price targets to $70, despite a slight pre-market dip in shares.
AtriCure Inc (A5I.HA) stock price, news, quote and history
This Yahoo Finance page provides detailed information for AtriCure Inc (A5I.HA) stock. It includes current stock price, recent performance data, key financial statistics, and a summary of recent news and earnings calls. The stock is currently trading at 57.00 EUR, up 11.76%.
AtriCure, Inc. Stock 12‑Month Price Target Raised to $66.75, Implies 10% Upside
The average 12-month price target for AtriCure, Inc. stock has increased from $61.71 to $66.75, implying a potential 10% upside based on the Nov. 3 closing price. This updated target is based on estimates from 8 analysts, with forecasts ranging from $57 to $70 per share. The consensus rating for ATRC remains "Buy" across 9 covering analysts.
AtriCure Reports Third Quarter 2026 Financial Results
AtriCure, Inc. reported strong third-quarter 2026 financial results, with worldwide revenue increasing 15.0% year over year to $154.5 million and net income reaching $4.1 million. The company's profitability expanded, driven by growth in U.S. revenue from pain management and appendage management devices, despite a decline in minimally invasive ablation sales. AtriCure also provided updated full-year 2026 financial guidance, projecting revenue between $606 million and $610 million.
AtriCure Reports Third Quarter 2026 Financial Results
AtriCure, Inc. announced strong third quarter 2026 financial results, with worldwide revenue reaching $154.5 million, a 15.0% increase year-over-year, and significant profitability expansion, including net income of $4.1 million and adjusted EBITDA of $26.8 million. The company's U.S. revenue growth was driven by its cryoSPHERE® MAX™ probe, EnCompass® clamp, and AtriClip FLEX-Mini® and PRO-Mini® devices, while minimally invasive ablation sales saw a decline due to physician adoption of PFA catheters. AtriCure also raised its full-year 2026 financial guidance for revenue and adjusted EBITDA, anticipating continued positive cash generation.
AtriCure to participate in 2026 Wells Fargo Health Care Conference
AtriCure, Inc. (NASDAQ: ATRC) announced its participation in the 2026 Wells Fargo Health Care Conference, where management will hold a fireside chat on September 8, 2026, at 10:15 am ET. A live audio webcast will be available on the company's investor relations website. The company specializes in surgical treatments for atrial fibrillation and left atrial appendage management, including its FDA-approved Isolator Synergy Ablation System and widely sold AtriClip products.
AtriCure Releases Q3 2026 Financial Results
AtriCure, Inc. (ATRC) significantly exceeded analyst expectations for Q3 2026, reporting adjusted earnings per diluted share of $0.17 against estimates of $0.01 and revenue of $154.4M, beating the $151.2M consensus. This strong performance, driven by a 15.0% year-over-year revenue increase and robust demand for its open ablation products, led management to issue optimistic FY 2026 guidance. Wall Street maintains a largely positive outlook with 7 buy ratings and 4 hold ratings.
AtriCure Q3 Revenue Rises 15% to $154.5 Million; Net Income Reaches $4.1 Million
AtriCure reported strong third-quarter 2026 results with revenue increasing 15% year-over-year to $154.5 million and net income reaching $4.1 million. The company saw gross margin expand to 77.3% and adjusted EBITDA jump 51% to $26.8 million. AtriCure projects full-year revenue between $606 million and $610 million, driven by growth in U.S. sales and international operations.
What AtriCure (ATRC) Said on Its Q3 Earnings Call
AtriCure (ATRC) reported strong third-quarter 2026 results with revenue up 15% year-over-year to $154.5 million, driven by growth in its U.S. open ablation, appendage management, and pain management businesses. The company saw significant increases in net income and adjusted EBITDA, raising its full-year revenue and adjusted EBITDA guidance. AtriCure also highlighted clinical trial progress and product development, including a new AtriClip FLEX-Mini device and ongoing rollout of cryoXT for pain management.
AtriCure Inc (A5I.HA) stock major holders - Yahoo Finance
This Yahoo Finance page provides information on the major holders of AtriCure Inc (A5I.HA) stock. It includes a breakdown of shares held by insiders and institutions, as well as the number of institutions holding shares. The page also mentions the company's Q3 2026 earnings call scheduled for today.
AtriCure Inc (A5I.HA) company profile and facts - Yahoo Finance
This Yahoo Finance page provides a profile for AtriCure Inc (A5I.HA), listing its current stock price and key dates. It notes that the company's Q3 2026 earnings call is scheduled for November 3, 2026, and indicates that detailed information regarding key executives, company description, and corporate governance scores is not available.
AtriCure Inc (A5I.HA) Valuation Measures & Financial Statistics
This article provides valuation measures and financial statistics for AtriCure Inc (A5I.HA), including current market capitalization, various P/E ratios, and price-to-sales. It also lists key financial highlights such as profitability, management effectiveness, income statement details, balance sheet items, cash flow, and trading information. The report notes AtriCure's upcoming Q3 2026 earnings call on November 3, 2026.
AtriCure, Inc. (ATRC) Seasonal returns chart
This article provides a seasonal returns chart for AtriCure, Inc. (ATRC), showing average monthly price returns from 2016 to 2026. It also includes current stock information, financial data, and details about their upcoming Q3 2026 earnings call.
How (ATRC) Movements Inform Risk Allocation Models
This article analyzes Atricure Inc. (NASDAQ: ATRC) movements, providing insights into risk allocation models. It highlights strong sentiment supporting an overweight bias and details three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
AtriCure, Inc. (ATRC) Seasonal returns chart
This article provides a seasonal returns chart for AtriCure, Inc. (ATRC), showing the average monthly price return from 2016 to 2026. It also includes current stock information, indicating a closing price of $61.25 with a 1.97% decrease on October 30, and details about an upcoming Q3 2026 earnings call.
AtriCure, Inc. (ATRC) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for AtriCure, Inc. (ATRC), displaying the average monthly price return from 2016 to 2026. It includes current stock information for ATRC, showing its real-time price and after-hours trading data. The page also features general market data for Canadian, US, European, and Asian markets, along with various financial indices and commodities.
AtriCure stock hits 52-week high at 61.71 USD
AtriCure Inc. (ATRC) stock has reached a new 52-week high of $61.71, driven by a 68.81% increase over the past year and strong recent momentum. While the company demonstrates robust growth with nearly 14% revenue growth and a 76.3% gross profit margin, InvestingPro data suggests the stock may be overvalued. Analysts have issued varied ratings and price targets, reflecting ongoing interest in the company's performance and clinical trials.
Left Atrial Epicardial Clips Market Size, Share, Trends 2036
The global left atrial epicardial clips market is projected to grow from USD 342.5 million in 2026 to USD 661.3 million by 2036, at a CAGR of 6.8%. This growth is driven by updated heart surgery guidelines recommending external clip placement for patients with irregular heart rhythms during bypass or valve repair, and the increasing adoption of nitinol braided-polyester clips due to their gentle tissue cushioning properties. Australia is expected to lead national expansion with a 7.5% CAGR, supported by high-volume combined mitral valve repair and private reimbursement.
AtriCure stock hits 52-week high at 61.71 USD By Investing.com
AtriCure Inc. (ATRC) stock has reached a new 52-week high of $61.71, reflecting a 68.81% increase over the past year and strong recent momentum. Despite this growth, InvestingPro data suggests the stock may be overvalued. Analysts have issued varied ratings and price targets, with several firms raising targets based on promising pipeline developments and clinical trial progress, while one downgraded to "Hold."
AtriCure stock hits 52-week high at 61.71 USD By Investing.com
AtriCure Inc. (ATRC) stock has reached a new 52-week high of $61.71, reflecting a 68.81% increase over the past year and substantial gains recently. Despite this strong performance and positive analyst ratings, InvestingPro data suggests the stock may be overvalued. The company continues to show robust revenue growth and gross profit margins, with ongoing progress in clinical trials.
AtriCure Inc (A5I.MU) stock price, news, quote and history
This Yahoo Finance page provides a detailed overview of AtriCure Inc (A5I.MU) stock, including its current price, historical data, and performance metrics. As of October 30, 2026, the stock was trading at 55.50 EUR, up 0.91%, with an upcoming Q3 2026 earnings call scheduled for November 3, 2026. The page also features a performance comparison against the S&P 500 benchmark for various timeframes.
AtriCure, Inc. Estimates – NASDAQ:ATRC
This article provides an overview of AtriCure, Inc. (NASDAQ: ATRC) financials and analyst estimates available on TradingView. It details how users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The platform explicitly states that the information provided is not investment advice.
AtriCure (ATRC) Jumps 75% In 90 Days, Is The Stock Now Too Expensive?
AtriCure (ATRC) has seen a significant rally, jumping 74.76% in the last 90 days, bringing its year-to-date gain to 46.86% and its 1-year total shareholder return to 55.40%. Despite this surge to US$57.67, Simply Wall St's valuation narrative suggests the stock is 49% overvalued with a fair value of $38.60, indicating that current prices reflect high expectations for future growth and clinical program success. Investors are advised to review the numbers and form their own stance, considering both the optimistic sentiment and valuation concerns.
Citizens JMP Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $68
Citizens JMP has reiterated its Buy rating on AtriCure (ATRC.US) and increased its price target from $65 to $68. This update reflects the firm's continued confidence in the medical device company.
Citizens raises AtriCure stock price target to $68 on pipeline By Investing.com
Citizens has increased its price target for AtriCure Inc. (NASDAQ:ATRC) to $68 from $52, maintaining a Market Outperform rating, driven by the company's clinical and product pipeline opportunities expected by 2028. AtriCure's shares have gained significantly year-to-date, reflecting investor appreciation for its growth prospects, particularly within its Pain Management segment. Despite appearing overvalued by some metrics, the firm remains bullish due to strong growth and upcoming product launches like cryoXT.
Citizens maintains Market Outperform rating on AtriCure, $68 price target
Citizens maintained a Market Outperform rating on AtriCure's stock, setting a price target of $68.00, which suggests an 17.9% upside from the recent closing price. The positive outlook is attributed to strong progress in clinical trials like BoxX-NoAF and LeAAPS, and a robust revenue growth outlook driven by the Pain Management and Open Ablation divisions. AtriCure is also expected to see expanded adjusted EBITDA margins and improved free cash flow conversion.
Citizens raises AtriCure stock price target to $68 on pipeline
Citizens has increased its price target for AtriCure Inc. (NASDAQ:ATRC) to $68 from $52, maintaining a Market Outperform rating due to appreciation of the company's clinical and product pipeline opportunities, particularly in its Pain Management segment. AtriCure's shares have risen significantly year-to-date, trading near a 52-week high, although InvestingPro analysis suggests the stock is currently overvalued. Other analysts have also adjusted their ratings and price targets for AtriCure, citing trial progress and new quality measures.
Citizens raises AtriCure stock price target to $68 on pipeline By Investing.com
Citizens has increased its price target for AtriCure Inc. (NASDAQ:ATRC) to $68 from $52, maintaining a Market Outperform rating, due to investor appreciation for the company's clinical and product pipeline. The medical device company's shares have risen significantly year-to-date, trading near its 52-week high, with its Pain Management segment showing strong growth. Despite appearing overvalued by some analyses, Citizens remains bullish, anticipating further upside from new product launches and deeper market penetration.
AtriCure (ATRC) Leans On Trial Progress As Fair Value Sits Just Below The Stock
AtriCure (ATRC) has gained investor attention due to recent share price surges, though its fair value of $54.89 suggests it is slightly overvalued compared to its current price of $56.87. The company's future growth prospects are tied to the success of its LeAAPS and BoxX-NoAF clinical trials, which could expand its market. However, risks like reduced surgical ablation volumes due to pulsed field ablation adoption and pricing pressures overseas remain.
AtriCure (ATRC) Leans On Trial Progress As Fair Value Sits Just Below The Stock
AtriCure (ATRC) has seen significant share price gains recently, making investors reconsider its valuation. While the company's fair value of $54.89 suggests it is slightly overvalued compared to its current price of $56.87, positive developments in its LeAAPS and BoxX-NoAF clinical trials could expand its market and drive future growth. Investors should, however, consider potential risks like the adoption of pulsed field ablation and overseas pricing pressures.